CD274 and neoplasm: PD-L1 expression in tumor or tumor infiltrating immune cells are used as an adjunct diagnostic criteria for the application of PD-1/PD-L1 pathway inhibitors (Muro et al., 2016), but the prognostic value of PD-L1 is controversial in GC patients (Liu et al., 2020).